Stamford, CT -- (SBWIRE) -- 10/01/2013 -- High Rising Stocks provides investors with the hottest penny stock alerts on a regular basis. Our Penny Stock Newsletter will send you alerts through our Free E Newsletters with High Yielding alerts, market forecasting, stock tips and strategies, and offer you the tools to help you along the way with the goal of keeping you loyal to our service. Today’s stocks to watch are: Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Myriad Genetics, Inc. (NASDAQ:MYGN), Geron Corporation (NASDAQ:GERN)
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) ended lower -58.29% and complete the day at $3.02. The total number of shares changed hands during the day was 38.85 million. After opening at $3.44, the stock hit as high as $3.62. However, it traded between $2.87 and $11.36 over the last twelve months. Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes anti-infective drug therapies in the United States and internationally.
Has ACHN Found The Bottom and Ready To Move Up? Find Out Here
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) closed yesterday at $5.27, a -8.98% decrease. Around 11.38 million shares were traded, beating an-average trading volume of 4.49 million shares. The company is now valued at around $1.15 billion. Arena Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing novel drugs that target G protein-coupled receptors in the therapeutic areas of cardiovascular, central nervous system, inflammatory, and metabolic diseases.
Has ARNA Found The Bottom And Ready To Gain Momentum? Find Out Here
Myriad Genetics, Inc. (NASDAQ:MYGN) moved -9.34 percent lower at $23.50 and traded between $22.61 and $26.10 after opening the day at $25.93. Its performance over the last five days remained -6.34%, which stands at -10.2% for a month. Going back further than one month, 1-year performance after recent close was -13.76%. Myriad Genetics, Inc., a molecular diagnostic company, focuses on the development and marketing of predictive medicine, personalized medicine, and prognostic medicine tests primarily in the United States.
Why Should Investors Buy MYGN After the Recent Fall? Just Go Here and Find Out
Geron Corporation (NASDAQ:GERN)’s shares dropped -9.46percent to close at $3.35. The stock is up around +7.37% this year and +7.37% for the last 12 months. Around 3.79 million shares changed hands yesterday, higher from an-average trading volume of 1.63 million shares. Geron Corporation is a clinical stage biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The company was founded in 1990 and is based in Menlo Park, California.
Will GERN Get Buyers Even After The Recent Rally? Find Out Here
High Rising Stocks is always searching the market every day for massive penny stock runs before they happen so you don't have to. We will send you alerts through our Free E Newsletters with High Yielding alerts, market forecasting, stock tips and strategies, and offer you the tools to help you along the way with the goal of keeping you loyal to our service.
Carriage Consulting Group, High Rising Stocks, their Members, officers, directors, employees, affiliates, or any other related person(s) (collectively, “High Rising Stocks”) are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. High Rising Stocks as defined are neither licensed nor qualified to provide investment advice and you are specifically and adamantly advised not to rely upon anything said/posted/communicated/implied or expressed by High Rising Stocks as defined.
Read full Disclaimer at: http://highrisingstocks.com/disclaimer/
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)